Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6550370 | 0.98 | HSD17B10 (0.50) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL2916590 | 0.91 | HSD17B10 (0.45) | HSD17B10SLC6A9TSHRGAAKDM4E | |
| Tetraxetan SCHEMBL2017956 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL173508 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL3503521 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL6848102 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL321989 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| Tetraxetan SCHEMBL18018 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| Tetraxetan SCHEMBL2635294 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 | |
| SCHEMBL6744121 | 0.81 | HSD17B10 (0.64) | HSD17B10SLC6A9TSHRGAAS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2776407-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2014-09-17 | — | — | EP | claimed |
| EP-2499129-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-07-30 | — | — | EP | claimed |
| EP-1981892-B1 | THIENO-PYRIDINE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA SA (BE) | 2014-03-12 | — | — | EP | claimed |
| US-8653105-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | claimed |
| US-8637543-B2 | Quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-01-28 | — | — | US | claimed |
| EP-2499144-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2013-10-23 | — | — | EP | claimed |
| WO-2013070657-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-17 | — | — | US | claimed |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2013-01-10 | — | — | US | claimed |
| US-6596687-B1 | For treatment of many inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-07-22 | — | — | US | claimed |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-06-26 | — | — | US | claimed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | claimed |
| WO-2003022815-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-03-20 | — | — | WO | claimed |
| JP-2003502405-A | — | — | 2003-01-21 | — | — | JP | claimed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | claimed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | claimed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | claimed |
| US-5614535-A | Adhesion receptor antagonists | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-03-25 | — | — | US | claimed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018057-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, CDK3, MAP3K13 | HSD17B10 4522/4885SLC6A9 4857/4885TSHR 3001/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | HSD17B10 1790/4885SLC6A9 3825/4885TSHR 1688/4885 |
| US-20130012517-A1 | Quinoline and Quinoxaline Derivatives as Kinase Inhibitors | PDXK, MAP2K2, PDPK1 | HSD17B10 3083/4885SLC6A9 4712/4885TSHR 3025/4885 |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | HSD17B10 1383/4885SLC6A9 4684/4885TSHR 3870/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | HSD17B10 3719/4885SLC6A9 800/4885TSHR 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.